A2A Adenosine Receptor Antagonists: Are Triazolotriazine and Purine Scaffolds Interchangeable?
作者:Andrea Spinaci、Catia Lambertucci、Michela Buccioni、Diego Dal Ben、Claudia Graiff、Maria Cristina Barbalace、Silvana Hrelia、Cristina Angeloni、Seyed Khosrow Tayebati、Massimo Ubaldi、Alessio Masi、Karl-Norbert Klotz、Rosaria Volpini、Gabriella Marucci
DOI:10.3390/molecules27082386
日期:——
The A2A adenosine receptor (A2AAR) is one of the four subtypes activated by nucleoside adenosine, and the molecules able to selectively counteract its action are attractive tools for neurodegenerative disorders. In order to find novel A2AAR ligands, two series of compounds based on purine and triazolotriazine scaffolds were synthesized and tested at ARs. Compound 13 was also tested in an in vitro model
A 2A腺苷受体 (A 2A AR) 是由核苷腺苷激活的四种亚型之一,能够选择性地抵消其作用的分子是治疗神经退行性疾病的有吸引力的工具。为了寻找新的 A 2A AR 配体,合成了基于嘌呤和三唑并三嗪支架的两个系列化合物,并在 ARs 进行了测试。还在神经炎症的体外模型中测试了化合物13 。发现一些化合物对 A 2A AR 具有高亲和力,并观察到化合物13在小胶质细胞中发挥抗炎作用。分子模型研究结果与结合亲和力数据非常一致,并强调只有当三唑并三嗪部分的 5 位和 2 位(对应于嘌呤 2 位和 8 位)被取代时,三唑并三嗪和嘌呤支架才可互换。